Ascentage Pharma Group (AAPGV): Price-to-Projected Revenue Ratio
Ascentage Pharma Group delegates protein synthesis and early-stage testing to external contractors, focusing on developing therapies to combat oncology and age-related pathologies. The forward P/S multiple helps assess the stock value relative to future sales, with the value of 8.50 serving as the current indicator. Olverembatinib provides a stable cash flow, confirming the high commercial value of the company's patent portfolio.
Ascentage - analytical breakdowns and key metrics (AAPGV)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- company liabilities and liquidity data:
Debt to Equity Ascentage Pharma Group|AAPGV - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Ascentage Pharma Group|AAPGV - Company Cumulative Indebtedness|Debts to Book Capitalization Ascentage|AAPGV - Company Long-Term Debts|Company Short-Term Debts Ascentage Pharma|Quick Ratio ascentage.com
- financial results and valuation multiples details:
AAPGV - Company Net Income|Future Profit Ascentage Pharma Group|AAPGV - Company Value to Net Income|Future Price to Earnings Ascentage Pharma Group Ltd|AAPGV - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Ascentage|AAPGV - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Ascentage Pharma|AAPGV - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months ascentage.com|AAPGV - Earnings per share increase in current year|Net earnings per share growth forecast for next year Ascentage Pharma Group
- sales and revenue data:
General company analysis:Ascentage Pharma AAPGV
Investments in elite apoptosis specialists and the large-scale expansion of laboratories at Ascentage Pharma Group (AAPGV) drive the high valuation of future developments. By analyzing the projected P/S trend, investors can discern market revenue expectations for the coming year, where the ratio of market capitalization to forecasted sales filters out price volatility, enabling a real-time assessment of the fundamental value of this high-tech biopharmaceutical asset.
Competitors of Ascentage Pharma Group
Forward P/S Multiple ONC (BeiGene)|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RVMD - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Ascentage Pharma Corp AAPG|CGON: Forward P/S Multiple|Forward Price-to-Revenue Multiple urogen.com|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Personalis Inc PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|Delcath Corp - Market Cap to Projected Revenue|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AURA (aurabiosciences.com)|Candel - Forward P/S Multiple|ARAY - Forward P/S Multiple|SLS: Forward P/S Multiple|Projected Price to Revenue Actuate Therapeutics Inc ACTU|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio TuHURA HURA|Forward Price-to-Revenue Multiple TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|TCRX (TScan Therapeutics Inc) - Future Price to Revenue|Champions Oncology Corp - Forward P/S Multiple|Forward Price to Sales XBIT (XBiotech Inc.)|CVM: Forward P/S Multiple|OS Therapies Inc. (OSTX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|ARTV: Forward Price to Sales|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|Forward Price-to-Revenue Multiple verupharma.com VERU|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|Forward P/S Multiple Xilio Therapeutics Inc XLO|RENB: Forward Price-to-Revenue Multiple|Forward Price to Sales MURA (Mural Oncology plc)|KAPA: Forward P/S Multiple|Projected Price to Revenue OnKure Therapeutics OKUR|Price-to-Projected Revenue Ratio CytoMed Therapeutics Ltd|CRIS: Forward Price to Sales|Price-to-Projected Revenue Ratio Apollomics, Inc. (APLM)|THAR - Market Cap to Future Revenue Ratio|Advanced Biomed - Forward Price-to-Revenue Multiple|Forward P/S Multiple genprex.com GNPX|CLDI - Price-to-Projected Revenue Ratio|Future Price to Revenue SBFM|XBIO: Forward P/S Multiple|Salarius Pharma (SLRX) - Forward P/S Multiple|PPBT (Purple Biotech) - Forward P/S Multiple|Forward P/S Multiple AON|Price-to-Projected Revenue Ratio BeiGene (BGNE)|CKPT: Future Price to Revenue|Forward P/S Multiple ELEV (Elevation Oncology, Inc.)|Projected Price to Revenue iCAD Inc.|IKNA: Forward Price-to-Revenue Multiple|NTBL: Price-to-Projected Revenue Ratio|VIRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple MorphoSys Inc|NAYA (NAYA Bio) - Forward P/S Multiple
